Analyst Michael Okunewitch of Maxim Group maintained a Buy rating on Longeveron (LGVN – Research Report), retaining the price target of $6.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Michael Okunewitch has given his Buy rating due to a combination of factors surrounding Longeveron’s promising developments and strategic positioning. The company is nearing the completion of its ELPIS II study for laromestrocel (Lomecel-B), which is crucial for treating hypoplastic left heart syndrome (HLHS). With enrollment at 95%, the study is expected to complete soon, and the topline data anticipated in mid-2026 could lead to a Biologics License Application (BLA) filing and potential approval in 2027. This progress is bolstered by the company’s preparations for commercialization and the highly concentrated nature of the HLHS market, which requires a relatively small commercial team.
Additionally, Longeveron has secured FDA alignment on a pivotal trial design for Alzheimer’s disease, which could attract partnerships with larger companies due to its streamlined nature. The company’s financial position, with sufficient funding into the third quarter of 2025, and the grant funding offsetting study expenses further support the Buy rating. These strategic moves and the potential for significant advancements in both HLHS and Alzheimer’s disease contribute to the positive outlook for Longeveron’s stock.
In another report released on May 6, Roth MKM also maintained a Buy rating on the stock with a $10.00 price target.